Novavax (NVAX) Revenue Growth (3y) (2013 - 2026)
Powered by 
Analysis
Novavax (NVAX) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 10.17% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 10.76% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 77.85% |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -25.02% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 42.02% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 59.40% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 7.80% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 76.62% |
| 10 | Novavax | 1.67 Bn | 948.56 Mn | 42.45 Mn | -48.88% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -48.88% |
| Mar 31, 2026 | 19.89% |
| Dec 31, 2025 | -25.61% |
| Sep 30, 2025 | -54.23% |
| Jun 30, 2025 | 8.77% |
| Mar 31, 2025 | -1.80% |
| Dec 31, 2024 | -26.48% |
| Sep 30, 2024 | -22.11% |
| Jun 30, 2024 | 11.71% |
| Mar 31, 2024 | -40.57% |
| Dec 31, 2023 | 1.37% |
| Sep 30, 2023 | 5.99% |
| Jun 30, 2023 | 128.58% |
| Mar 31, 2023 | 188.33% |
| Dec 31, 2022 | 243.53% |
| Sep 30, 2022 | 564.19% |
| Jun 30, 2022 | 281.18% |
| Mar 31, 2022 | 461.24% |
| Dec 31, 2021 | 231.00% |
| Sep 30, 2021 | 184.89% |